| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 150% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 06/16/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | Neutral → Neutral |
| 05/30/2023 | 525% | Ladenburg Thalmann | $4 → $10 | Maintains | Buy |
| 05/09/2023 | 150% | Cantor Fitzgerald | $2 → $4 | Maintains | Overweight |
| 03/30/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | → Neutral |
| 10/07/2022 | 25% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 12/03/2021 | 400% | Cantor Fitzgerald | $5 → $8 | Maintains | Overweight |
| 12/01/2021 | 400% | Jefferies | → $8 | Initiates Coverage On | → Buy |
| 08/03/2021 | 118.75% | Mizuho | $4 → $3.5 | Maintains | Neutral |
| 07/16/2021 | 275% | HC Wainwright & Co. | $9.5 → $6 | Maintains | Buy |
| 05/27/2021 | 525% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/26/2021 | 493.75% | HC Wainwright & Co. | $12 → $9.5 | Maintains | Buy |
| 02/10/2021 | 150% | Mizuho | $7 → $4 | Downgrades | Buy → Neutral |
| 10/06/2020 | 650% | HC Wainwright & Co. | $10 → $12 | Maintains | Buy |
| 03/13/2020 | 400% | Wedbush | $11 → $8 | Maintains | Outperform |
| 03/10/2020 | 525% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 09/12/2019 | 337.5% | Mizuho | → $7 | Initiates Coverage On | → Buy |
| 05/29/2019 | 275% | Roth Capital | → $6 | Initiates Coverage On | → Buy |
What is the target price for Corvus Pharma (CRVS)?
The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $4.00 expecting CRVS to rise to within 12 months (a possible 150.00% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corvus Pharma (CRVS)?
The latest analyst rating for Corvus Pharma (NASDAQ: CRVS) was provided by Cantor Fitzgerald, and Corvus Pharma reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating Corvus Pharma (CRVS) correct?
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a reiterated with a price target of $0.00 to $4.00. The current price Corvus Pharma (CRVS) is trading at is $1.60, which is within the analyst's predicted range.